By comparing the transcriptomic profile of tissue regeneration after induced damage in the small intestine and colon with their transcriptomic landscape in their steady state, researchers have identified a pathway that unlinks tissue regeneration from tumorigenesis. Read More
Arovella Therapeutics Ltd. is heading toward the clinic with its lead product, ALA-101, which consists of a chimeric antigen receptor (CAR) targeting CD19 and invariant natural killer T (iNKT) cells. Read More
Rectify Pharmaceuticals Inc. has conducted preclinical testing on RTY-694, an oral dual-targeted positive functional modulator for use in the treatment of hepatobiliary disorders. Read More
The company analyzed genomic data provided by the Fred Hutch Cancer Center and compiled by the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) to identify mutational signatures and single nucleotide polymorphisms (SNPs) predictive of colorectal cancer. Read More
Beijing Danatlas Pharmaceutical Technology Co. Ltd. has disclosed Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer. Read More
The collaboration aims to identify a small molecule that targets mutant androgen receptor (AR) mRNA splicing and causes selective destruction of the disease-causing mRNA. Read More
To address limitations with CAR T therapies targeting CD19, Allogene Therapeutics Inc. has developed ALLO-329, a CD19/CD70-targeting CAR therapy that is able to deplete activated alloreactive lymphocytes, while endowing dual targeting of CD19+ B cells and CD70+ T cells. Read More
Genzyme Corp. (Sanofi Genzyme) has identified receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of Alzheimer’s disease, multiple sclerosis, amyotrophic lateral sclerosis and Parkinson’s disease. Read More
Potent siRNAs against B4GALT1 were designed in silico and screened in vitro (Huh7 cells, primary mouse, human hepatocytes) as well as in vivo (C57BL/6 mice) for the selection of a lead Galomic siRNA. Read More
Beijing Danatlas Pharmaceutical Technology Co. Ltd. has divulged DNA polymerase θ (POLθ) inhibitors reported to be useful for the treatment of cancer. Read More
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has described pyrrolobenzodiazepine compounds reported to be useful for the treatment of cancer. Read More
Researchers from SL Bigen Inc. and collaborators presented the preclinical characterization of BM-205, a novel entity of engineered MSCs designed to exert antitumor functions. Read More
